Hyderabad, February 14, 2026 – NATCO Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) on Saturday announced that it has received approval from the Central Drugs Standard Control Organisation for Semaglutide in India, paving the way for the commercial launch of its generic Semaglutide Injection in March 2026.
The regulatory clearance enables the Hyderabad-based pharmaceutical major to manufacture and market the product in the domestic market. The development was disclosed to stock exchanges under Regulation 30 of the SEBI Listing Regulations.
Product Indication and Market Entry
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.With the March 2026 launch timeline, NATCO is set to enter the fast-growing anti-diabetic segment in India with a generic injectable formulation, expanding its domestic specialty portfolio.
About NATCO Pharma Limited
Headquartered in Hyderabad, NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.The company positions itself as an R&D-oriented and science-driven leading oncology player in the domestic targeted therapies market and focuses on limited competition molecules in the United States. It operates nine manufacturing facilities and two R&D centres in India. Its facilities are approved by leading global regulatory authorities including the U.S. FDA, Brazil ANVISA, Health Canada and WHO, catering to over 50 global markets.
NATCO shares trade on the BSE under Scrip Code 524816 and on the NSE under the symbol NATCOPHARM.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.